Siemens Healthineers confirms outlook despite problems at Varian
Revenue in the quarter gained 3.6% on a comparable basis, helped by growth in the Imaging and Advanced Therapies segments, to 5.1 billion euros, in line with analysts' expectations. Excluding the COVID-19 rapid antigen test business, comparable revenue growth was 10.1% for the April-June quarter. However, Siemens Healthineers lowered its profit margin outlook for Varian due to "temporary challenges in outbound logistics" at its U.S. maker of devices and software for treating cancer to 14-15% from a previous 16-18%.
Source: yahoo.com
